Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  AUSTRALIAN SECURITIES EXCHANGE LIMITED  >  CSL Limited    CSL   AU000000CSL8

CSL LIMITED (CSL)
Mes dernières consult.
Most popular
  Report  
 SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   End-of-day quote. End-of-day quote Australian Securities Exc…
02/12/2018 02/13/2018 02/14/2018 02/15/2018 02/16/2018 Date
140.26(c) 142.07(c) 149.29(c) 151.5(c) 153.39 Last
566 136 735 976 1 615 266 1 216 028 892 911 Volume
-0.14% +1.29% +5.08% +1.48% +1.25% Change
More quotes
Financials ($)
Sales 2018 7 559 M
EBIT 2018 2 179 M
Net income 2018 1 626 M
Debt 2018 3 355 M
Yield 2018 1,35%
Sales 2019 8 230 M
EBIT 2019 2 467 M
Net income 2019 1 885 M
Debt 2019 3 109 M
Yield 2019 1,53%
P/E ratio 2018 33,96
P/E ratio 2019 29,61
EV / Sales2018 7,73x
EV / Sales2019 7,07x
Capitalization 55 104 M
More Financials
Company
CSL Ltd. is a biopharmaceutical company.It engages in researches, develops, manufactures and markets vaccines and plasma protein biotherapies to treat and prevent human medical conditions.The company operates its business through two segments: CSL Behring and bioCSL.The CSL Behring segment provides... 
More about the company
Surperformance© ratings of CSL Limited
Trading Rating : Investor Rating :
More Ratings
Latest news on CSL LIMITED
01/25CSL : Study Findings from CSL Limited Broaden Understanding of Obesity, Fitness ..
AQ
01/22New drugs recast $10 billion haemophilia market as Sanofi swoops in
RE
01/04CSL : Researchers Submit Patent Application, "Method of Treatment of Philadelphi..
AQ
2017CSL : Behring Advances to Phase 3 Cardiovascular Outcomes Trial for CSL112, its ..
AQ
2017CSL : Appoints New Directors
PU
2017CSL : Expansion of CSL Biotech Facility Drives Advanced Manufacturing Growth and..
PU
2017CSL : and Vitaeris Announce Strategic Partnership with Option to Acquire
PU
2017CSL : Confirms Phase 3 Clinical Trial of New Therapy for Heart Attack Survivors
PU
2017CSL : Lancet Neurology Publishes Results from CSL Behring Phase III Study of Hiz..
AQ
2017CSL : Major UK investment to boost influenza vaccine production, jobs and export..
AQ
More news
Sector news : Biopharmaceuticals
02/16S&P 500 caps off strongest week in five years
RE
02/16ASTRAZENECA : U.S. FDA approves AstraZeneca's immunotherapy for lung cancer
RE
02/16NOVARTIS : readies to auction U.S. generic pills business - sources
RE
02/16Backstory - Warren Buffett's Valentine's Day surprise for investors
RE
02/16WARREN BUFFETT : Warren Buffett's Valentine's Day surprise for investors
RE
More sector news : Biopharmaceuticals
Latest Tweets
02/17Candriam Luxembourg S.C.A. Invests $4.14 Million in Carlisle Companies, Inc. .. 
02/16Today’s @TCIHQ Overview, on the markets, reporting season, Telstra, CSL, Barn..
1
02/16NEW EARNINGS RESULTS THIS WEEK: $ANN, $AZJ, $BEN, $JBH, $TCL, $COH, $CSL, $IA.. 
02/16$CSL - Carlisle Companies #CSL Upgraded by Zacks Investment Research to "Hold.. 
02/15Carlisle Companies, Inc. $CSL Plans Quarterly Dividend of $0.37  
More tweets
Qtime:174
News from SeekingAlpha
02/14CSL Ltd. ADR 2018 Q2 - Results - Earnings Call Slides 
2017CSL (CSLLY) Investor Presentation - Slideshow 
2017CSL Limited Leader In High Growth Plasma Sales To China 
2017CSL reports Q2 results 
2017CSL (CMXHF) Acquires Wuhan Zhong Yuan Rui De Biological Products - Slideshow 
Chart CSL LIMITED
Duration : Period :
CSL Limited Technical Analysis Chart | CSL | AU000000CSL8 | 4-Traders
Technical analysis trends CSL LIMITED
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 10
Average target price 123 $
Spread / Average Target 0,98%
EPS Revisions
Managers
NameTitle
Paul Roger Perreault Chief Executive Officer, Executive Director & MD
Brian Anthony McNamee Chairman-Elect
David Mark Lamont Chief Financial Officer
Andrew Cuthbertson Chief Scientific Officer
David Westbrook Anstice Independent Non-Executive Director
Sector and Competitors
1st jan.Capitalization (M$)
CSL LIMITED7.22%54 288
BIOGEN-7.06%63 312
ALEXION PHARMACEUTICALS3.02%27 311
GRIFOLS SA-4.40%18 471
BIOMARIN PHARMACEUTICAL-5.19%14 847
CHONGQING ZHIFEI BIOLOGICAL PRDCT CO LTD--.--%6 679